<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04125732</url>
  </required_header>
  <id_info>
    <org_study_id>XC001-1001</org_study_id>
    <nct_id>NCT04125732</nct_id>
  </id_info>
  <brief_title>Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)</brief_title>
  <acronym>EXACT</acronym>
  <official_title>A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human VEGF, to the Ischemic Myocardium of Subjects With Angina Pectoris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XyloCor Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XyloCor Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients
      who suffer from angina caused by coronary artery disease and have no other treatment options.
      Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses
      human vascular endothelial growth factor (VEGF) which induces therapeutic angiogenesis
      (revascularization).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2, first-in-human, multicenter, open-label, single arm dose escalation
      trial of XC001. Approximately 12 subjects (N=3 per cohort) who have refractory angina will be
      enrolled into 4 ascending dose groups, followed by an expansion of the highest tolerated dose
      with 17 additional subjects. XC001 will be administered by a transthoracic epicardial
      procedure. Safety will be the focus for the initial 6 months after XC001 administration
      followed by one safety focused telephone evaluation at Month 12.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint (adverse events)</measure>
    <time_frame>6 months</time_frame>
    <description>Safety, as assessed by adverse events and serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint (Exercise tolerance test)</measure>
    <time_frame>6 months</time_frame>
    <description>Exercise tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint (Seattle Angina Questionnaire)</measure>
    <time_frame>6 months</time_frame>
    <description>Seattle Angina Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint (Canadian Cardiovascular Society angina class)</measure>
    <time_frame>6 months</time_frame>
    <description>Canadian Cardiovascular Society angina class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint (Angina episodes)</measure>
    <time_frame>6 months</time_frame>
    <description>Angina episodes</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Ischemia</condition>
  <condition>Angina Refractory</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>AdVEGFXC1 at 1x10^9 vp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AdVEGFXC1 at 1x10^10 vp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AdVEGFXC1 at 4x10^10 vp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AdVEGFXC1 at 1x10^11 vp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AdVEGFXC1</intervention_name>
    <description>AdVEGFXC1 at one of 4 doses</description>
    <arm_group_label>AdVEGFXC1 at 1x10^10 vp</arm_group_label>
    <arm_group_label>AdVEGFXC1 at 1x10^11 vp</arm_group_label>
    <arm_group_label>AdVEGFXC1 at 1x10^9 vp</arm_group_label>
    <arm_group_label>AdVEGFXC1 at 4x10^10 vp</arm_group_label>
    <other_name>XC001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, age 18 to 80 years

          -  Diagnosis of chronic angina due to obstructive coronary artery disease that is
             refractory to drug therapy and unsuitable for revascularization via coronary artery
             bypass graft or percutaneous coronary intervention

          -  Angina class II-IV based on Canadian Cardiovascular Society Classification of Angina
             Pectoris

          -  Adequate hematologic (hemoglobin ≥ 10 g/dL, absolute neutrophil count &gt; 1.2 × 10^3 per
             μL and platelet count ≥ 75,000 per μL), hepatic (alanine aminotransferase and
             aspartate aminotransferase ≤ 3 x ULN; total bilirubin ≤ 2 x ULN), and renal function
             (glomerular filtration rate &gt; 29 mL/minute/1.73 m2)

          -  Adequate birth control if of child-bearing potential

          -  Must be willing and able to provide informed consent

        Exclusion Criteria:

          -  ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial infarction
             (NSTEMI) not requiring revascularization, transmural myocardial infarction or cerebral
             vascular accident within the past 30 days

          -  New York Heart Association Function Class III or IV or left ventricular ejection
             fraction &lt; 25% within the 6 weeks prior to the screening visit

          -  HbA1c ≥ 9.5%, SBP &lt;90 or &gt;180 mmHg, DBP &gt;100 mmHg

          -  Other concurrent medical conditions that could jeopardize the safety of the subject or
             objectives of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark Peterson</last_name>
    <phone>888-290-0081</phone>
    <email>mark.peterson@xylocor.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Kirkland</last_name>
    </contact>
    <investigator>
      <last_name>David Fortuin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kokil Bakshi</last_name>
    </contact>
    <investigator>
      <last_name>Joseph Woo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiology Research Associates</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauraine Crandall</last_name>
    </contact>
    <investigator>
      <last_name>David Henderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Long</last_name>
    </contact>
    <investigator>
      <last_name>David Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chari Ponder</last_name>
    </contact>
    <investigator>
      <last_name>Omar Lattouf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Jensen</last_name>
    </contact>
    <investigator>
      <last_name>Jay Traverse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Yuan</last_name>
    </contact>
    <investigator>
      <last_name>Michael Argenziano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Andrews</last_name>
    </contact>
    <investigator>
      <last_name>Tom Povsic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital / The Lindner Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Kishman</last_name>
    </contact>
    <investigator>
      <last_name>Tim Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey Piazza</last_name>
    </contact>
    <investigator>
      <last_name>Faisal Bakaeen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Johnson</last_name>
    </contact>
    <investigator>
      <last_name>Nahush Mokadam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daphney Reables</last_name>
    </contact>
    <investigator>
      <last_name>Tom MacGillivray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD, Rasmussen HS. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006 Nov;13(21):1503-11. Epub 2006 Jun 22.</citation>
    <PMID>16791287</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 4, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory angina</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Gene Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

